Gleevec (STI-571) for chronic myeloid leukemia.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005252:Fees, Pharmaceutical; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010879:Piperazines / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate